NTRA News and Press, Natera Inc. From 04/28/22

NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natera, Inc. ("Natera" or the "Company") (NASDAQ:NTRA) and reminds investors of the June 27, 2022 deadline to seek the role of lead plain...

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD) PR Newswire RenaCARE study expected to be fully enrolled by end of Q2 of 2022 AUSTIN, Texas , April 26, 202...

NEW YORK, NY / ACCESSWIRE / April 19, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natera, Inc. ("Natera" or the "Company") (NASDAQ:NTRA) . If you suffered losses exceeding $50,000 investing in Natera stock or options ...

The U.S. FDA is warning that non-invasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when in actuality the fetus was healthy. The agency noted that these tests, which are also known as noninvasive prenatal tests (NIPT), ha...

Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease PR Newswire AUSTIN, Texas , April 19 , 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA ...

SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2022 / Hagens Berman urges Natera, Inc. (NASDAQ:NTRA) investors who suffered significant losses to submit your losses now . The firm is investigating possible violations of the securities laws. Visit: www.hbsslaw.com/investor-fraud/NTRA Co...

Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection PR Newswire DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples AUSTIN, Texas ...

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting PR Newswire Signatera ctDNA dynamics are both predictive and prognostic in neoadjuvant TNBC. Lead time up to 30 months betwe...

San Francisco, California--(Newsfile Corp. - April 7, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now . The firm is investigating possible violations of the securities laws. Visit: www.hbsslaw.com/investor-fraud...

Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test PR Newswire AUSTIN, Texas , April 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the ...